← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	877	-2	-0.2%	$18.7B
2	2 Charles River Laboratories CRL $14.4B	284	-2	-0.7%	$3.85B
3	3 DELISTED CATALENT, INC. CTLT	202	+16	+9%	$3.31B
4	4 DELISTED bluebird bio BLUE	201	+24	+14%	$3.02B
5	ISEE 5 DELISTED IVERIC bio, Inc. Common Stock ISEE	192	+10	+5%	$1.59B
6	6 Sarepta Therapeutics SRPT $1.78B	188	+40	+27%	$2.6B
7	7 Ultragenyx Pharmaceutical RARE $1.47B	174	+12	+7%	$2.8B
8	8 Precigen PGEN $2.64B	169	0	0%	$2.82B
9	9 DELISTED SANGAMO THERAPEUTICS INC SGMO	125	-11	-8%	$204M
10	10 PTC Therapeutics PTCT $4.98B	116	-2	-2%	$409M
11	AGTC 11 DELISTED Applied Genetic Technologies Corporation AGTC	95	+1	+1%	$102M
12	SIOX 12 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	95	+14	+17%	$1.43B
13	13 Lineage Cell Therapeutics LCTX $232M	80	+6	+8%	$153M
14	14 Rocket Pharmaceuticals RCKT $243M	78	+12	+18%	$207M
15	15 DELISTED Adverum Biotechnologies ADVM	76	-1	-1%	$62.7M
16	16 Atara Biotherapeutics ATRA $96M	76	+2	+3%	$479M
17	ATHX 17 DELISTED Athersys, Inc. Common Stock ATHX	73	-5	-6%	$30.6M
18	18 Regenxbio RGNX $454M	71	+2	+3%	$237M
19	BLCM 19 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	70	+3	+4%	$371M
20	20 Intellia Therapeutics NTLA $1.6B	65	+3	+5%	$243M
21	21 Voyager Therapeutics VYGR $124M	53	+5	+10%	$128M
22	22 Fortress Biotech FBIO $63.4M	51	-1	-2%	$21.2M
23	23 uniQure QURE $1.45B	49	-10	-17%	$54.1M
24	24 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	48	+10	+26%	$628M
25	ADAP 25 DELISTED Adaptimmune Therapeutics ADAP	46	-1	-2%	$218M